ERBB2 co-amplification was observed in 13.1% to 24.5% of tumors harboring ERBB2 activating mutations, suggesting that mutations can serve as the primary genomic mechanism of ERBB2 activation in multiple tumor types (Fig. 2D). The gene discussed is ERBB2; the disease is neoplasm.